US and EU Regulatory Compliance for Absorbent Hygiene Products: A 2026 B2B Importer's Guide

Regulatory risk is the most underestimated variable in B2B absorbent hygiene procurement. While wholesale buyers focus on unit pricing, SAP performance, and delivery lead times, a single regulatory non-compliance event — a detained container at a US port, a rejected shipment under EU MDR, or a PFAS violation notice — can erase months of margin.

The regulatory landscape for adult incontinence products, Underpads, and absorbent hygiene items is tightening across both the US and EU in 2026. Nonwovens Industry's February 2026 feature "State and Federal Action to Watch in 2026: Absorbent Hygiene Products" — an article that generated exceptionally high engagement among industry professionals — catalogued a wave of new legislative and regulatory actions that B2B importers cannot afford to ignore.

This article provides a structured, actionable compliance framework for B2B buyers importing Adult Diapers, pull-up pants, and disposable underpads into the US and EU markets.

US Federal Developments: Ingredient Disclosure and FDA Oversight

The Menstrual Products Right to Know Act — And Why Adult Incontinence Buyers Should Care

In early 2026, Congresswoman Grace Meng reintroduced the Menstrual Products Right to Know Act, with Representative Anna Paulina Luna as Republican co-lead. The bill would amend the Federal Food, Drug, and Cosmetic Act to deem menstrual products "misbranded" if their labeling does not list all components of the finished product in order of predominance by weight.

While the bill's current scope is limited to menstrual products, three factors make it directly relevant to adult incontinence B2B buyers:

1. Legislative precedent: Once a federal ingredient disclosure framework is established for one absorbent hygiene category, extension to adult incontinence is a logical and likely next step. Industry observers expect adult diaper ingredient labeling requirements within 3–5 years.

2. State-level spillover: Virginia's HB 998 already applies ingredient labeling and chemical restrictions to menstrual products. State legislatures often serve as laboratories for federal policy — and several states are watching Virginia's implementation closely.

3. Consumer expectation convergence: The transparency expectations created by menstrual product labeling will inevitably influence adult incontinence purchasing. B2B buyers who require full material disclosure from suppliers now will have a competitive compliance advantage.

FDA Draft Guidance on Menstrual Products (October 2025)

The FDA released new draft guidance in October 2025 to update oversight of menstrual products, replacing its 2005 guidance. Key updates include:

• Full ingredient disclosure on outer packaging
• Expanded evaluation of potential contaminants
• Clarified methods for assessing Toxic Shock Syndrome (TSS) risk
• Recommendations specific to menstrual cups

B2B takeaway: While adult incontinence products classified as Class I medical devices already follow FDA 510(k) requirements, the regulatory direction of travel — toward full ingredient transparency, contaminant testing, and clinical performance data — will raise the compliance baseline for all absorbent hygiene categories.

US State-Level Action: PFAS, EPR, and Ingredient Bans

State legislatures are entering 2026 with a sharpened focus on chemical safety and life-cycle accountability for consumer products. The following actions have direct implications for adult incontinence B2B importers:

PFAS Restrictions

Multiple states have enacted or proposed bans on intentionally added PFAS (per- and polyfluoroalkyl substances) in consumer products. While adult diapers are not typically formulated with PFAS, the following product components require supply chain verification:

The most conservative and operationally simplest approach: require a "No Intentionally Added PFAS" certificate from every raw material supplier in your adult diaper supply chain. This documentation protects against both regulatory action and reputational risk.

Extended Producer Responsibility (EPR)

Several states are advancing EPR frameworks that would require producers of disposable products to fund end-of-life waste management. While EPR legislation has primarily targeted packaging to date, absorbent hygiene products are under active discussion in Maine, Oregon, and California.

B2B implication: EPR costs, when implemented, will be passed through the supply chain — from manufacturer to importer to distributor to retailer. B2B buyers should begin modeling a 2–5% cost adder for EPR compliance in US-bound shipments within the 2027–2029 timeframe.

EU Regulatory Landscape: MDR, REACH, and the Circular Economy

Medical Device Regulation (MDR) 2017/745

Adult incontinence products classified as Class I medical devices under EU MDR must comply with specific requirements that differ from general consumer goods:

Mandatory documentation for EU importers:

1. EC Declaration of Conformity: Issued by the manufacturer, declaring compliance with applicable requirements of MDR Annex I (General Safety and Performance Requirements).

2. Technical Documentation per MDR Annex II: Must include product description, design and manufacturing information, verification and validation test reports (including biocompatibility per ISO 10993), and clinical evaluation data.

3. CE Marking: Affixed to the product or packaging per MDR Annex V requirements.

4. Unique Device Identification (UDI) : Required for all Class I devices. The UDI-DI (device identifier) plus UDI-PI (production identifier including lot number, expiry date) must be registered in the EUDAMED database.

5. Person Responsible for Regulatory Compliance (PRRC) : The manufacturer must have a qualified person responsible for ensuring conformity per Article 15 of the MDR.

Common compliance failure points for non-EU OEM suppliers:

• Biocompatibility testing per ISO 10993-5 (cytotoxicity) and ISO 10993-10 (skin irritation/sensitization) not completed or documentation expired
• Clinical evaluation report (CER) absent or insufficient for the device's risk class
• UDI not registered in EUDAMED
• Labeling not translated into required EU official languages

B2B verification action: Request a copy of the supplier's current EC Declaration of Conformity and the notified body certificate (if applicable) before placing any EU-bound order. Verify the certificate's validity period — expired documentation is the single most common cause of EU customs rejection.

REACH Regulation (EC) 1907/2006

REACH governs chemical substances manufactured in or imported into the EU. For adult incontinence products, the key REACH obligations are:

• SVHC (Substances of Very High Concern) screening: Verify that no component — SAP, nonwoven fabric, adhesives, elastic materials, wetness indicator dyes, lotions — contains SVHC above the 0.1% weight-by-weight threshold.

• Article 33 communication duty: If any SVHC is present above threshold, the importer must communicate this to downstream customers and, upon request, to consumers within 45 days.

• SCIP database submission: Products containing SVHC above 0.1% w/w must be registered in the SCIP database under the Waste Framework Directive.

Practical compliance approach: Obtain a full REACH compliance statement from each raw material supplier, with explicit confirmation that no SVHC exceeds 0.1% w/w. Maintain these statements in a compliance file organized by lot number for traceability.

EU Circular Economy Action Plan — Digital Product Passport

The European Commission's Circular Economy Action Plan includes a requirement for Digital Product Passports (DPP) for textiles and, by extension, disposable absorbent hygiene products. The DPP will require:

• Material composition disclosure at component level
• Recycled content percentage
• Presence of substances of concern
• Repair and disassembly information
• End-of-life handling instructions

The implementation timeline targets 2027–2028 for textiles, with hygiene products likely included in subsequent phases. B2B buyers should begin collecting the data required for DPP compliance now — material composition, recycled content, substance declarations — as this data will not be retroactively reconstructable without supplier cooperation.

Practical Compliance Checklist for B2B Importers

For Every US-Bound Adult Incontinence Shipment:

• Supplier FDA establishment registration and device listing active and current
• Product classified correctly as Class I medical device with appropriate product code
• Labeling compliant with 21 CFR Part 801 (ingredient statement, manufacturer identity, net quantity)
• "No Intentionally Added PFAS" certification on file
• Packaging materials compliant with state-level PFAS restrictions in destination states
• California Proposition 65 assessment completed for all product components

For Every EU-Bound Adult Incontinence Shipment:

• Valid EC Declaration of Conformity on file
• Technical documentation per MDR Annex II complete and accessible
• Biocompatibility test data (ISO 10993-5, ISO 10993-10) current
• UDI-DI registered in EUDAMED; UDI-PI on product labeling
• CE marking correctly applied
• Full REACH compliance statement from each raw material supplier
• SVHC screening completed; SCIP database submission if applicable
• Labeling in required official languages of destination member states

Conclusion

Regulatory compliance for adult incontinence B2B imports is no longer a one-time certification exercise — it is an ongoing, dynamic process that requires active supplier management and documentation hygiene.

The three most important actions a B2B importer can take in 2026:

1. Audit your OEM supplier's regulatory documentation — specifically the EC Declaration of Conformity expiry date, FDA device listing status, and REACH compliance statements. Do not rely on assurances; verify with primary documents.

2. Implement a "No Intentionally Added PFAS" supply chain certification program — require this declaration from every raw material supplier and maintain it in a lot-traceable compliance file.

3. Begin collecting Digital Product Passport data now — material composition, recycled content, and substance declarations — so your products are DPP-ready when the requirement goes into effect.

At Wholesome Hygiene, our OEM and ODM adult incontinence products are manufactured under ISO 13485 quality management, with full MDR technical documentation, FDA device listing, and REACH compliance maintained for every product SKU. Contact our B2B team for a compliance documentation package specific to your target market.